VENTURA COUNTY
HEALTH CARE PLAN

SOLIRIS (eculizumab)

Effective Date: 1/28/14
Date Developed: 1/28/14 by Robert Sterling, MD
Last Approved Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19
(Archived 1/22/19)

Soliris is a monoclonal antibody which inhibits intravascular hemolysis by selectively binding to C5, thereby inactivating its cleavage to active components

Authorization: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (aHUS; not related to infectious causes)

Dosing: PNH/aHUS: 600/900 mg IV weekly x4 weeks, then 900/1200 mg one week later then 900/1220 mg IV every two weeks thereafter **Note:** For patients lees than 18 years of age, refer to product literature for weight-based dosing

PRECAUTIONS: Higher risk of menningococcal infections (boxed warning) and infections with other encapsulated organisms (make sure patient is vaccinated at least two weeks prior to initiation of therapy); prescriber must enroll in Risk Evaluation and Mitigation Strategy (REMS; 888-765-4747); use of eculizumab should not alter any anticoagulation therapy

DRUG INTERACTIONS: Immunosuppressants may enhance effect

REFERENCES

Brodsky RA, "How I Treat Paroxysmal Nocturnal Hemoglobinuria," *Blood*, 2009, 113(26):6522-7.b

Brodsky RA, Young NS, Antonioli E, et al, "Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria," *Blood*, 2008, 111(4):1840-7.

Centers for Disease Control and Prevention, "Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP)," *MMWR Recomm Rep*, 2005, 54(RR-7):1-21.

Hill A, Hillmen P, Richards SJ, et al, "Sustained Response and Long-Term Safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria," *Blood*, 2005, 106(7):2559-65

Hill A, Hillmen P, Richards SJ, et al, "Sustained Response and Long-Term Safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria," *Blood*, 2005, 106(7):2559-65

Taylor CM, Machin S, Wigmore SJ, et al, "Clinical Practice Guidelines for the Management of Atypical Haemolytic Uraemic Syndrome in the United Kingdom," *Br J Haematol*, 2010, 148(1):37-47.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C/ Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C/ Sanders, MD; R/ Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C/ Sanders, MD; R/ Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C/ Sanders, MD; R/ Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG